Peter Lau

7PUBLICATIONS
25CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsNanomedicineApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Oct 27, 2026
An Australian Narrative Review of Adoptive Cellular Therapies in Malignancy: Expanding Indications, Referral Pathways and Safety Beyond Specialist Centres.

|Mar 02, 2022
Adaptive translational reprogramming of metabolism limits the response to targeted therapy in BRAFV600 melanoma.

Lorey K Smith, Tiffany Parmenter, Margarete Kleinschmidt

|Oct 09, 2021
Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES).

Peter Kar Han Lau, Breon Feran, Lorey Smith

|Dec 11, 2020
Combined BRAF, MEK, and CDK4/6 Inhibition Depletes Intratumoral Immune-Potentiating Myeloid Populations in Melanoma.

Emily J Lelliott, Stefano Mangiola, Kelly M Ramsbottom

|Jan 17, 2020
Activation of Canonical BMP4-SMAD7 Signaling Suppresses Breast Cancer Metastasis.

Bedrich L Eckhardt, Yuan Cao, Andrew D Redfern

|Apr 03, 2019
Bevacizumab as a steroid-sparing agent during immunotherapy for melanoma brain metastases: A case series.

Patricia D Banks, Arian Lasocki, Peter K H Lau

Pageof 2

Frequent Collaborators

3 joint publications

Karen E Sheppard

2 joint publications

Arian Lasocki

2 joint publications

Bruce Latham

1 joint publications

Mark Shackleton